SCOPE FLUIDICS SA ZY-10 - Asset Resilience Ratio
SCOPE FLUIDICS SA ZY-10 (S84) has an Asset Resilience Ratio of 32.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See S84 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how SCOPE FLUIDICS SA ZY-10's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of SCOPE FLUIDICS SA ZY-10.
Liquid Assets Composition Over Time
This chart breaks down SCOPE FLUIDICS SA ZY-10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SCOPE FLUIDICS SA ZY-10 balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €63.77 Million | 32.55% |
| Total Liquid Assets | €63.77 Million | 32.55% |
Asset Resilience Insights
- Very High Liquidity: SCOPE FLUIDICS SA ZY-10 maintains exceptional liquid asset reserves at 32.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SCOPE FLUIDICS SA ZY-10 Industry Peers by Asset Resilience Ratio
Compare SCOPE FLUIDICS SA ZY-10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
Check-Cap Ltd
F:7CC |
Diagnostics & Research | 2.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Annual Asset Resilience Ratio for SCOPE FLUIDICS SA ZY-10 (2023–2025)
The table below shows the annual Asset Resilience Ratio data for SCOPE FLUIDICS SA ZY-10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.55% | €63.77 Million ≈ $74.56 Million |
€195.94 Million ≈ $229.07 Million |
+19.71pp |
| 2024-12-31 | 12.84% | €22.19 Million ≈ $25.94 Million |
€172.87 Million ≈ $202.10 Million |
-7.76pp |
| 2023-12-31 | 20.60% | €20.90 Million ≈ $24.44 Million |
€101.49 Million ≈ $118.65 Million |
-- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.